June 2019 FDA Recall Drug by Preferred Pharmaceuticals, Inc
D-1410-2019 - CGMP Deviations

This Class II drug recall was voluntarily initiated by Preferred Pharmaceuticals, Inc on June 10, 2019 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed in Distribution was made to CA and FL. and the recall is currently terminated.

Recall Number: D-1410-2019

Reason for Recall
CGMP Deviations: Potential product contamination with Burkholderia cepacia (B.cepacia) and Ralstonia pickettii (R. pickettii).
Initiated
06-10-2019
Reported
06-26-2019
Quantity
192 4 oz bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Preferred Pharmaceuticals, Inc
Distribution was made to CA and FL.
Robafen DM, Generic for Robitussin DM, In each teaspoonful (5mL): Dextromethorphan HBr, USP 10mg,/Guaifenesin, USP 100mg, 118mL (4oz) bottle, Manufactured for Preferred Pharmaceuticals, Inc., Anaheim, CA 92807 by Major Pharmaceuticals, Livonia, MI 48152, NDC 68788-0841-01

Batch or Lot Expiration Information

Lot# Lot: J0218L, Batch: 10021812, Exp. 02/2020; Lot: L2718D, Batch numbers from consecutively from L2718D001 to L2718D096, Exp. 07/2020